CDR Grafted Antibody for Radioimmunotherapy of Lymphoma

Award Information
Agency:
Department of Health and Human Services
Amount:
$750,000.00
Program:
SBIR
Contract:
1 R43 CA66348-01,
Solitcitation Year:
N/A
Solicitation Number:
N/A
Branch:
N/A
Award Year:
1996
Phase:
Phase II
Agency Tracking Number:
29202
Solicitation Topic Code:
N/A
Small Business Information
Immunomedics, Inc.
300 American Road, Morris Plains, NJ, 07950
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
N/A
Principal Investigator
 Gary Griffiths
 () -
Business Contact
Phone: () -
Research Institution
N/A
Abstract
This Phase I research will test the hypothesis that an optimum, commercially viable radioimmunotherY-90-radiolabeled cdr-grafted LL2 MAb, targeted against radiosensitive Non-Hodgkin's lymphoma. Y-90because of its desirable radiophysical properties, possible use on an out-patient basis and commercicdr-grafted MAb has been selected in order to minimize human anti-mouse antibody response, which coutreatment. Conjugates will be radiolabeled using a bifunctional chelate based on 2-benzyl-DTPA, sincbe performed in 93- 98 percent incorporation yields within l hour. Y-90-labeled cdr-grafted LL2 willradiolabeled murine LL2 and to the corresponding radioiodinated antibodies for stability; in vitro cinternalization and isotope cellular retention studies, and in vivo in animal tumor xenograft modelsPhase I period, the investigators will have either confirmed the suitability of the Y-90- labeled cdradioimmunotherapy or decided that one of the other agents would be preferred, based on the combinedtumor targeting studies. The final goal is a clinically efficacious, commercially useful, radioimmun

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government